Biomonitoring of estrogen and melatonin metabolites among women residing near radio and television broadcasting transmitters

Journal of Occupational and Environmental Medicine

Volumn 49, Issue 10, 2007, Pages 1149-1156

  Clark, Maggie L ^a   Burch, James B ^b   Yost, Michael G ^c   Zhai, Yusheng ^b   Bachand, Annette M ^a   Fitzpatrick, Cole T E ^c   Ramaprasad, Jaya ^c   Cragin, Lori A ^a   Reif, John S ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTRONE GLUCURONIDE; MELATONIN;

ADULT; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; ESTROGEN URINE LEVEL; FEMALE; HORMONE RESPONSE; HORMONE URINE LEVEL; HUMAN; MAGNETIC FIELD; MALE; NORMAL HUMAN; PARAMETER; POSTMENOPAUSE; PREMENOPAUSE; RADIATION; RADIATION EXPOSURE; RADIOFREQUENCY RADIATION; RESIDENTIAL HOME; TELECOMMUNICATION; TELEVISION; URINALYSIS; URINARY EXCRETION; VISIBILITY;

EID: 37349065807     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181566b87     Document Type: Article

References (78)

1. Krewski D, Byus CV, Glickman BW, et al. Potential health risks of radiofrequency fields from wireless telecommunication devices. J Toxicol Environ Health B Crit Rev. 2001;4:1-143.
2. Ahlbom A, Green A, Kheifets L, Savitz D, Swerdlow A. Epidemiology of health effects of radiofrequency exposure. Environ Health Perspect. 2004;112:1741-1754.
3. Portier CJ, Wolfe MS, eds. Assessment of Health Effects from Exposure to Power-Line Frequency Electric and Magnetic Fields. Department of Health and Human Services Publication. NIH Publication Number 98-3981. Research Triangle Park, NC: National Institute of Environmental Health Sciences; 1998.
4. Feychting M, Forssen U. Electromagnetic fields and female breast cancer. Cancer Causes Control. 2006;17:553-558.
5. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987;125:556-561.
6. Caplan LS, Schoenfeld ER, O'Leary ES, Leske MC. Breast cancer and electromagnetic fields-a review. Ann Epidemiol. 2000;10:31-44.
7. Henshaw DL, Reiter RJ. Do magnetic fields cause increased risk of childhood leukemia via melatonin disruption? Bioelectromagnetics. 2005;Suppl 7:S86-S97.
8. Burch JB, Reif JS, Noonan CW, Yost MG. Melatonin metabolite levels in workers exposed to 60-Hz magnetic fields: work in substations and with 3-phase conductors. J Occup Environ Med. 2000;42:136-142.
9. Burch JB, Reif JS, Noonan CW, et al. Melatonin metabolite excretion among cellular telephone users. Int J Radiat Biol. 2002;78:1029-1036.
10. Cagnacci A, Volpe A. Influence of melatonin and photoperiod on animal and human reproduction. J Endocrinol Invest. 1996;19:382-411.
11. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
12. Okatani Y, Morioka N, Wakatsukin A. Changes in nocturnal melatonin secretion in perimenopausal women: correlations with endogenous estrogen concentrations. J Pineal Res. 2000;28:111-118.
13. Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol. 2001;36:297-310.
14. Schernhammer ES, Rosner B, Willett WC, et al. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev. 2004;13:936-943.
15. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prevent. 2000;9:575-579.
16. Toniolo PG. Endogenous estrogens and breast cancer risk: the case for prospective cohort studies. Environ Health Perspect. 1997;105:587-592.
17. Key TJA, Wang DY, Brown JB, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer. 1996;73:1615-1619.
18. Helzlsouer KJ, Alberg AJ, Bush TL, et al. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994;18:79-85.
19. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol. 1994;140:518-525.
20. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res. 2005;38:217-222.
21. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst. 2005;97:1084-1087.
22. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005;65:11174-11184.
23. Burch JB, Clark M, Yost G, et al. Radio frequency non-ionizing radiation in a community exposed to radio and television broadcasting. Environ Health Perspect. 2005;114:248-253.
24. Burch JB, Reif JS, Yost MG, Keefe TJ, Pitrat CA. Nocturnal excretion of a urinary melatonin metabolite among electric utility workers. Scand J Work Environ Health. 1998;24:183-189.
25. Wood AW, Armstrong SM, Sait ML. Changes in human plasma melatonin profiles in response to 50 Hz magnetic field exposure. J Pineal Res. 1998;25:116-127.
26. Burch JB, Reif JS, Yost MG, Keefe TJ, Pitrat CA. Reduced excretion of a melatonin metabolite in workers exposed to 60 Hz magnetic fields. Am J Epidemiol. 1999;150:27-36.
27. Yost MG. Alternative magnetic field exposure metrics: occupational measurements in trolley workers. Radiation Protection Dosimetry. 1999;83:99-106.
28. Ichinose TY, Burch JB, Noonan CW, et al. Immune markers and ornithine decarboxylase activity among electric utility workers. J Occup Environ Med. 2004;46:104-112.
29. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocr Metab. 1985;60:1166-1173.
30. Aldous ME, Arendt J. Radioimmunoassay for 6-sulphatoxymelatonin in urine using an iodinated tracer. Ann Clin Biochem. 1988;25:298-303.
31. O'Connor KA, Brindle E, Shofer JB, et al. Statistical correction for non-parallelism in a urinary enzyme immunoassay. J Immunoassay Immunochem. 2004;25:259-278.
32. Denari JH, Farinati Z, Figueroa Casas PR, Oliva A. Determination of ovarian function using first morning urine steroid assays. Obstet Gynecol. 1981;58:5-9.
33. Merlo AB, Farinati Z, Quiroga S, et al. Direct assay of urinary steroid glucuronides for monitoring the approach of ovulation. Int J Fertil. 1984;29:189-193.
34. Wilcox AJ, Baird DD, Weinberg CR, et al. The use of biochemical assays in epidemiologic studies of reproduction. Environ Health Perspect. 1987;75:29-35.
35. Catalan R, Castellanos JM, Palomino T, et al. Correlation between plasma estradiol and estrone-3-glucuronide in urine during the monitoring of ovarian induction therapy. Int J Fertil. 1989;34:271-275.
36. Miller RC, Brindle E, Holman DJ, et al. Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations. Clin Chem. 2004;50:924-932.
37. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women's health. Epidemiol Rev. 1995;17:265-286.
38. Windham GC, Elkin E, Fenster L, et al. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology. 2002;13:675-684.
39. O'Connor KA, Brindle E, Holman DJ, et al. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research. Clin Chem. 2003;49:1139-1148.
40. Wilson BW, Wright CW, Morris JE, et al. Evidence for an effect of ELF electromagnetic fields on human pineal gland function. J Pineal Res. 1990;9:259-269.
41. Davis S, Kaune WT, Mirick DK, Chen C, Stevens RG. Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol. 2001;154:591-600.
42. Levallois P, Dumont M, Touitou Y, et al. Effects of electric and magnetic fields from high-power lines on female urinary excretion of 6-sulfatoxymelatonin. Am J Epidemiol. 2001;154:601-609.
43. Davis S, Mirick DK, Chen C, Stanczyk FZ. Effects of 60-Hz magnetic field exposure on nocturnal 6-sulfatoxymelatonin, estrogens, luteinizing hormone, and follicle-stimulating hormone in healthy reproductive-age women: results of a crossover trial. Ann Epidemiol. 2006;166:22-31.
44. Maskarinec G, Cooper J, Swygert L. Investigation of increased incidence in childhood leukemia near radio towers in Hawaii: preliminary observations. J Environ Pathol Toxicol Oncol. 1994;13:33-37.
45. Hocking B, Gordon IR, Grain HL, Hatfield GE. Cancer incidence and mortality and proximity to TV towers. Med J Aust. 1996;165:601-605.
46. Dolk H, Shaddick G, Walls P, et al. Cancer incidence near radio and television transmitters in Great Britain. I. Sutton Coldfield transmitter. Am J Epidemiol. 1997;145:1-9.
47. Dolk H, Elliott P, Shaddick G, Walls P, Thakrar B. Cancer incidence near radio and television transmitters in Great Britain. II. All high power transmitters. Am J Epidemiol. 1997;145:10-17.
48. McKenzie DR, Yin Y, Morrell S. Childhood incidence of acute lymphoblastic leukaemia and exposure to broadcast radiation in Sydney - a second look. Aust N Z J Public Health. 1998;22:360-367.
49. Michelozzi P, Capon A, Kirchmayer U, et al. Adult and childhood leukemia near a high-power radio station in Rome, Italy. Am J Epidemiol. 2002;155:1096-1103.
50. Park SK, Ha M, Im HJ. Ecological study on residences in the vicinity of AM radio broadcasting towers and cancer death: preliminary observations in Korea. Int Arch Occup Environ Health. 2004;77:387-394.
51. Litovitz TA, Penafiel M, Krause D, Zhang D, Mullins JM. The role of temporal sensing in bioelectromagnetic effects. Bioelectromagnetics. 1997;18:388-395.
52. Illnerova H, Buresova M, Presl J. Melatonin rhythm in human milk. J Clin Endocrinol Metab. 1993;77:838-841.
53. Yie SM, Brown GM, Liu GY, et al. Melatonin and steroids in human pre-ovulatory follicular fluid: seasonal variations and granulosa cell steroid production. Hum Reprod. 1995;10:50-55.
54. Van Varuun RJ, Pitout MJ, Van aswegen CH. Putative melatonin receptor in human spermatozoa. Biochem. 1992;25:125-127.
55. Laudon M, Gilad E, Matzkin H, Braf Z, Zisapel N. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab. 1996;81:1336-1342.
56. Weaver DR, Stehle JH, Reppert SM. Melatonin receptors in human hypothalamus and pituitary: implications for circadian and reproductive responses to melatonin. J Clin Endocrinol Metab. 1993;76:295-301.
57. Silman R. Melatonin and the human gonadotrophin-releasing hormone pulse generator. J Endocrinol. 1991;128:7-11.
58. Berga SL, Mortola JF, Yen SS. Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab. 1988;66:242-244.
59. Brzezinski A, Lynch HJ, Seibel MM, et al. The circadian rhythm of plasma melatonin during the normal menstrual cycle and in amenorrheic women. J Clin Endocrinol Metab. 1988;66:891-895.
60. Voordouw BCG, Euser R, Verdonk RER, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74:108-117.
61. Okatani Y, Sagara Y. Amplification of nocturnal melatonin secretion in women with functional secondary amenorrhea: relation to endogenous oestrogen concentration. Clin Endicrinol. 1994;41:763-770.
62. Kripke DF, Kline LE, Shadan FF, et al. Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262. BMC Womens Health. 2006;6:8.
63. Vakkuri O, Kivela A, Leppaluoto J, Valtonen M, Kauppila A. Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol. 1996;135:188-192.
64. Fernandez B, Malde JL, Montero A, Acuna D. Relationship between adenohypophyseal and steroid hormones and variations in serum and urinary melatonin levels during the ovarian cycle, perimenopause and menopause in healthy women. J Steroid Biochem. 1990;35:257-262.
65. Graham C, Cook MR, Gerkovich MM, Sastre A. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect. 2001;109:501-507.
66. Schernhammer ES, Kroenke CH, Dowsett M, Folkerd E, Hankinson SE. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J Pineal Res. 2006;40:116-124.
67. Benhaberou-Brun D, Lambert C, Dumont M. Association between melatonin secretion and daytime sleep complaints in night nurses. Sleep. 1999;22:877-885.
68. Hakola T, Harma MI, Laitinen JT. Circadian adjustment of men and women to night work. Scand J Work Environ Health. 1996;22:133-138.
69. Burch JB, Yost MG, Johnson W, Allen E. Melatonin, sleep, and shift work adaptation. J Occup Environ Med. 2005;47:893-901.
70. Cos S, Martinez-Campa C, Mediavilla MD, Sanchez-Barcelo EJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 2005;38:136-142.
71. Cos S, Gonzalez A, Guezmes A, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer. 2006;118:274-278.
72. Martinez-Campa C, Gonzalez A, Mediavilla MD, et al. Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 2005;94:249-254.
73. Warman GR, Tripp HM, Warman VL, Arendt J. Circadian neuroendocrine physiology and electromagnetic field studies: precautions and complexities. Radiat Prot Dosimetry. 2003;106:369-373.
74. Touitou Y, Bogdan A, Lambrozo J, Selmaoui B. Is melatonin the hormonal missing link between magnetic field effects and human diseases? Cancer Causes Control. 2006;17:547-552.
75. Di Carlo AL, Litovitz TA. Is genetics the unrecognized confounding factor in bioelectromagnetics? Flock-dependence of field-induced anoxia protection in chick embryos. Bioelectrochem Bioenerg. 1999;48:209-215.
76. Fedrowitz M, Loscher W. Power frequency magnetic fields increase cell proliferation in the mammary gland of female Fischer 344 rats but not various other rat strains or substrains. Oncology. 2005;69:486-498.
77. Altpeter ES, Roosli M, Battaglia M, et al. Effect of short-wave (6-22 MHz) magnetic fields on sleep quality and melatonin cycle in humans: the Schwarzenburg shut-down study. Bioelectromagnetics. 2006;27:142-150.
78. Johansson O. Electrohypersensitivity: state-of-the-art of a functional impairment. Electromagn Biol Med. 2006;25:245-258.